New CEO takes up Position at NeMoDevices

Swiss medical technology company NeMoDevices AG, a developer of solutions for the simultaneous monitoring of critical brain oxygenation and circulation parameters, has appointed Dr Philippe Dro as Chief Executive Officer.

Dr. Dro previously served as CEO of GlycoVaxyn AG, a Swiss biotech startup in vaccines, which was acquired by GSK in early 2015. He was formerly CEO of EndoArt SA, a medical technology company spin-out from the École polytechnique fédérale de Lausanne (EPFL), which was acquired by Allergan in early 2007.

NeMoDevices has applied its proprietary platform based on Near-InfraRed Spectroscopy (NIRS) technology in two products: the minimally invasive NeMo Probe and the non-invasive NeMo Patch. The NeMo Probe received CE Mark approval in 2015. Dr Dro succeeds Dr. Michael Oberle, who will continue to support the company as COO.

“Philippe currently serves as Chairman of the Board of Directors. We are delighted that he is joining the Management Team as CEO and look forward to benefit from his product development and commercialisation experience to further accelerate the development of NeMoDevices.” said Prof. Emanuela Keller, founder and member of the company’s Board of Directors.

 “Having worked with the Management Team and the Board of Directors for a while, I was impressed by the potential of the platform and the people behind it. The products from NeMoDevices are providing physicians key information on brain blood flow and oxygen levels allowing to bridge the gap from merely monitoring to individualised patient treatment. I am thrilled to join this team and would like to thank Dr. Michael Oberle for his valuable contribution as CEO.” said Dr. Philippe Dro.